Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2023-12-18 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
第五届监事会第十七次临时会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of a resolution passed at a supervisory board meeting regarding the repurchase and cancellation of restricted shares. It includes details about the meeting date, participants, voting process, and the specific agenda item approved. The document does not contain financial statements or detailed financial data but serves as an official disclosure of a board decision. It references another announcement for more details, indicating this is a standalone announcement of a board resolution rather than a full report or financial filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other specific categories.
2023-12-18 Chinese
第五届董事会第二十三次临时会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting of Chongqing Porton Pharmaceutical Technology Co., Ltd. It details decisions such as the replacement of directors in subsidiaries and the repurchase and cancellation of restricted shares. The text includes voting results and references to related announcements but does not contain financial statements or detailed financial analysis. It is clearly about board decisions and management actions rather than a full report or financial disclosure. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, confirming this classification.
2023-12-18 Chinese
关于回购注销部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Chongqing Boteng Pharmaceutical Technology Co., Ltd. regarding the repurchase and cancellation of part of its restricted stock under the 2021 restricted stock incentive plan. It details the background, reasons, quantities, prices, and effects of the repurchase and cancellation of restricted shares due to certain incentive recipients no longer qualifying. The document includes board and supervisory committee meeting approvals and legal opinions. It is a corporate announcement about share repurchase and cancellation related to stock incentives, not a financial report, earnings release, or regulatory filing. The content fits the category of Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares.
2023-12-18 Chinese
监事会关于回购注销部分限制性股票的核查意见
Transaction in Own Shares Classification · 95% confidence The document is a supervisory board's verification opinion regarding the repurchase and cancellation of restricted shares. It references relevant laws and company regulations, and concludes on the legitimacy and impact of the repurchase. The content is focused on a specific transaction involving the company's own shares (repurchase and cancellation of restricted stock). The document length is short (537 characters), and it contains substantive content about the share repurchase, not just an announcement or a certification. Therefore, it fits best under the category of Transaction in Own Shares (POS).
2023-12-18 Chinese
关于公司高级管理人员辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a senior management member, specifically the company's vice general manager. It details the resignation date, shareholding information, and compliance with relevant laws and regulations. There is no financial data, report, or presentation included. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2023-12-03 Chinese
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is a progress announcement regarding the company's share repurchase plan. It details the number of shares repurchased, prices, compliance with regulatory guidelines, and the timeline of the repurchase activity. It does not contain financial statements or earnings data but focuses on the update of the share buyback program. This matches the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2023-12-03 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.